World Journal of
Pharmaceutical and Life Sciences

NEW PRINCIPLE BASED DEVELOPMENT OF NAPHTHOQUINONE AS AN UNIVERSAL PRVENTIVE DRUG(CODED AS GSPZ9) AGAINST SARS-COV-2S PROTEIN AND ITS VARIANTS

Dr. S. Sawhney*

ABSTRACT

Out of 30 trillion human cells, the only human lung cells had been endowed with furin protease attached with the
receptor (ACE2)- a central point to which the dormant SARS-CoV-2 S protein, evading the human body defences
including antibodies due to the defined spike protein glycosylation, accesses and attaches to furin protease without
any hindrance where S protein gets cleaved into S1 and S2 protein, which causes fusion to ACE2 and entry of the
virus into the human lung cell. These facts on SARS-CoV-2 S protein had been overlooked while evolving and
developing vaccination, which simply elicits antibodies for spike protein engulfment, and fail to perform
satisfactorily consequent to spike protein glycosylation. New principle-based an universal preventive
naphthoquinone drug (GSPZ9) has been found as the best option to combat SARS-CoV-2 S proteins and its
variants with no risk whatsoever The 5mg naphthoquinone as an oral dose twice a day with water or milk in order
to buildup the blood volume, and 8x10-3% w/w naphthoquinone in cream base, to apply intranasally have been
standardized. The intranasal application of naphthoquinone cream would neutralise the virus protein to stop its
entry beyond the intranasal limitation. The blood circulating naphthoquinone, acting as an additional body defence
against SARS-CoV-2 S protein neutralises it, and furin protease internally, overlying layers of naphthoquinone
over the proteins of both the players to prevent their union, and S protein cleaving into S1 and S2 proteins. If by
chance their union occurs, the blood circulating naphthoquinone would intervene and dehydrogenbond the weekly
hydrogenbonded proteins of the two players, and then strongly hydrogenbond both the players’ proteins to prevent
their remarrying.

[Full Text Article]   [Download Certificate]